5-methyl-2-hepten-4-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

5-methyl-2-hepten-4-one: shows an intense, hazelnut-like aroma; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	5362588
SCHEMBL ID	310233
SCHEMBL ID	310232
MeSH ID	M0368115

Synonyms (32)

Synonym
AKOS015841109
5-methyl-(e)-2-hepten-4-one
(2e)-5-methyl-2-hepten-4-one
5-methyl-2-hepten-4-one, predominantly trans, 98%, fg
5-methylhept-2-en-4-one
(e)-5-methylhept-2-en-4-one
5-methyl-2-hepten-4-one
81925-81-7
fema no. 3761
102322-83-8
5-methyl-2-hepten-4-one, predominantly trans
2-hepten-4-one, 5-methyl-, (e)-
5-methyl-2-hepten-4-one [fhfi]
(e)-5-methyl-2-hepten-4-one
(+/-)-filbertone
8k2s58736f ,
5-methyl-2-hepten-4-one, (+/-)-
unii-8k2s58736f
2-hepten-4-one, 5-methyl-, (2e)-
(+/-)-5-methyl-2-hepten-4-one
SCHEMBL310233
SCHEMBL310232
ARJWAURHQDJJAC-GQCTYLIASA-N
filbertone, (.+/-.)-
AC-33764
mfcd00792509
Q5448299
DTXSID401017670
filbertone,5-methyl-(e)-2-hepten-4-one
AS-76135
CS-W013495
HY-W012779

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (9.09)	18.2507
2000's	4 (36.36)	29.6817
2010's	4 (36.36)	24.3611
2020's	2 (18.18)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (9.09%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (90.91%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.08	1	pyrrole; secondary amine
n-heptane Heptanes: Seven-carbon alkanes with the formula C7H16.. heptane : A straight-chain alkane with seven carbon atoms. It has been found in Jeffrey pine (Pinus jeffreyi).	4.54	7	alkane; volatile organic compound	non-polar solvent; plant metabolite
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	2.08	1	diazine; pyrazines	Daphnia magna metabolite
deuterium Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.	2	1	dihydrogen
alkenes [no description available]	2.76	3
alpha-synuclein alpha-Synuclein: A synuclein that is a major component of LEWY BODIES and plays a role in SYNUCLEINOPATHIES, neurodegeneration and neuroprotection.	2.6	1

Condition	Relationship Strength	Studies
Degenerative Diseases, Central Nervous System [description not available]	2.6	1
Idiopathic Parkinson Disease [description not available]	2.6	1
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	2.6	1
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	2.6	1
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	2.6	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.05	1

chemdatabank.com